JPWO2020264211A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020264211A5
JPWO2020264211A5 JP2021576582A JP2021576582A JPWO2020264211A5 JP WO2020264211 A5 JPWO2020264211 A5 JP WO2020264211A5 JP 2021576582 A JP2021576582 A JP 2021576582A JP 2021576582 A JP2021576582 A JP 2021576582A JP WO2020264211 A5 JPWO2020264211 A5 JP WO2020264211A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576582A
Other languages
English (en)
Japanese (ja)
Other versions
JP7788859B2 (ja
JP2022538117A5 (https=
JP2022538117A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/039687 external-priority patent/WO2020264211A1/en
Publication of JP2022538117A publication Critical patent/JP2022538117A/ja
Publication of JP2022538117A5 publication Critical patent/JP2022538117A5/ja
Publication of JPWO2020264211A5 publication Critical patent/JPWO2020264211A5/ja
Priority to JP2025107324A priority Critical patent/JP2025175994A/ja
Application granted granted Critical
Publication of JP7788859B2 publication Critical patent/JP7788859B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576582A 2019-06-26 2020-06-25 がんを処置するための抗ｃｄ３３抗体 Active JP7788859B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107324A JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867032P 2019-06-26 2019-06-26
US62/867,032 2019-06-26
PCT/US2020/039687 WO2020264211A1 (en) 2019-06-26 2020-06-25 Anti-cd33 antibodies for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107324A Division JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Publications (4)

Publication Number Publication Date
JP2022538117A JP2022538117A (ja) 2022-08-31
JP2022538117A5 JP2022538117A5 (https=) 2023-07-03
JPWO2020264211A5 true JPWO2020264211A5 (https=) 2023-07-03
JP7788859B2 JP7788859B2 (ja) 2025-12-19

Family

ID=74059823

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576582A Active JP7788859B2 (ja) 2019-06-26 2020-06-25 がんを処置するための抗ｃｄ３３抗体
JP2025107324A Pending JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107324A Pending JP2025175994A (ja) 2019-06-26 2025-06-25 がんを処置するための抗ｃｄ３３抗体

Country Status (6)

Country Link
US (1) US20220251192A1 (https=)
EP (1) EP3990022A4 (https=)
JP (2) JP7788859B2 (https=)
CN (1) CN114401744B (https=)
CA (1) CA3149683A1 (https=)
WO (1) WO2020264211A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2021242848A1 (en) * 2020-05-27 2021-12-02 Memorial Sloan Kettering Cancer Center Anti-gd2 sada conjugates and uses thereof
EP4608871A1 (en) * 2022-10-26 2025-09-03 Memorial Sloan-Kettering Cancer Center Cd33 antibody compositions for treating alzheimer's disease
CN116375874B (zh) * 2023-04-14 2023-12-26 上海精翰生物科技有限公司 一种cd33抗体及其应用
CN118580357A (zh) * 2024-08-07 2024-09-03 上海交通大学医学院附属仁济医院 一种cd33特异性单克隆抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
BR0316101A (pt) * 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
CN106456762A (zh) * 2014-05-20 2017-02-22 伊缪诺金公司 用于表征和治疗急性髓样白血病的方法
SG10201913765YA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US10519248B2 (en) * 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CN108290939B (zh) * 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
US20190233534A1 (en) * 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2017355402A1 (en) * 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
US11583588B2 (en) * 2017-05-05 2023-02-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (SADA) technologies
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン， インコーポレイテッド 抗ｃｄ３３イムノコンジュゲート投与計画
US11565005B2 (en) * 2017-07-06 2023-01-31 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
CN111372610B (zh) * 2017-09-22 2023-05-30 伊缪诺金公司 防止免疫结合物中的甲硫氨酸氧化的方法
US20190153096A1 (en) * 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体

Similar Documents

Publication Publication Date Title
IL273484B1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
US11427648B2 (en) Anti-CD146 antibodies and uses thereof
Welt et al. Phase I study of anticolon cancer humanized antibody A33
JP5085005B2 (ja) 非コンジュゲートおよびコンジュゲート抗体、抗体の組合せおよび融合タンパク質を用いるｂ細胞悪性腫瘍および自己免疫疾患の免疫療法
JP5110768B2 (ja) モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用
JP2020523029A5 (https=)
JP2021517816A5 (https=)
JP5155356B2 (ja) モノクローナル抗体ｈＰＡＭ４
Chester et al. Engineering antibodies for clinical applications in cancer
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2020534017A5 (https=)
TR201901824T4 (tr) Rs7 Antikorları
CN115379848A (zh) 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂
Reddy et al. Immuno-positron emission tomography in cancer models
JPWO2020264211A5 (https=)
JPWO2020210232A5 (https=)
van Winkel et al. Molecular imaging supports the development of multispecific cancer antibodies
JPWO2021046331A5 (https=)
Lindland et al. Preclinical evaluation of PTK7-targeted radionuclide therapy
JPWO2021216972A5 (https=)
JPWO2020172621A5 (https=)
JPWO2021007371A5 (https=)
JPWO2022032004A5 (https=)
JPWO2019178218A5 (https=)
JPWO2023014809A5 (https=)